Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Direvo Reaches Milestone in Consolidated Bioprocessing of Lignocellulose to Lactic Acid

Published: Tuesday, March 12, 2013
Last Updated: Tuesday, March 12, 2013
Bookmark and Share
Company ferments lactic acid on pilot scale in a single-step-synthesis.

Direvo Industrial Biotechnology GmbH (Direvo) has announced that it has reached an important milestone in developing a consolidated bioprocess for lactic acid production from lignocellulose.

Up until now, there has not been any known consolidated bioprocess for producing lactic acid from lignocellulose.

Direvo has now successfully built up a processing chain from pretreatment through fermentation to downstream processing for a consolidated bioprocess for lactic acid.

On the basis of pretreated Miscanthus grass, Direvo fermented lactic acid on pilot scale in a single-step-synthesis.

Direvo was further able to show that the important step of downstream processing of free lactic acid in the fermentation matrix can be realized efficiently by standardized procedures.

The downstream processing was executed in collaboration with the department of bioengineering of the Leibniz Institute for Agricultural Engineering Potsdam-Bornim.

Direvo’s specific, self-isolated proprietary microorganism Caldicellulosiruptor sp. produces the needed enzymes to ferment the pretreated biomass and converts the emerging sugar to end products.

In these processes, no cost-intensive technical enzymes have to be added.

A further advantage is that these microorganisms are extreme thermophile and therefore high process temperatures don’t cause product losses through contamination with foreign bacteria.

On the basis of this proof-of-concept, the next development stage to raise competitiveness in a commercial environment will be to increase the yield of lactic acid.

Consolidated bioprocessing is the conversion of lignocellulose into target products in a single step without having to add enzymes.

Direvo develops consolidated bioprocesses for production of biofuels and biobased chemicals under the brand name BluCon®.

Beside Lactic Acid, BluCon®-L, Direvo pursues with Ethanol, BluCon®-E, another product line.

BluCon® converts various non-food biomass ranging from grasses and straw to agricultural and wood residues and can therefore be applied around the globe.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!